Page 132 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $1.90
52wk Low $0.52 Ocugen, Inc. OCGN $1.14
11 Great Valley Parkway
Malvern, PA 19355

(USD - in millions) www.ocugen.com
Market Cap 356.0
Enterprise 356.4
Basic Shares Out. 312.32 COMPANY OVERVIEW
Float 307.65
Institutional Holdings 14.82% Detailed Analysis:Channelchek.com
Short Interest 58.01
Avg. 90-Day Volume 4.72 Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene therapies to address
major blindness diseases and offer hope for patients across the globe.
We are making an impact on patient’s lives through courageous
EPS Data innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene therapy
2022 2023 2024 platform has the potential to address significant unmet medical need
CQ1 (0.09) (0.07) (0.05) for large patient populations through our gene-agnostic approach.
CQ2 (0.09) (0.10) (0.04)

CQ3 (0.10) (0.06) (0.05)
CQ4 (0.10) (0.03) (0.05)
CY (0.38) (0.26) (0.20) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.01
ROE (ttm) -289.93
Debt-to-Total Cap. (mrq) 90.32
Fiscal Year End 31-Dec
11 Great Valle Malvern PA 19355

Key Executives
CEO: Musunuri, Shankar
CFO: Ramachandran, Ramesh
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures